"Phase 1 Study of Tru-016, An Anti-CD37 SMIP™ Protein in Naïve and Relapsed and/or Refractory CLL Patients" by Farrukh T Awan

Selected Works of John M. Pagel, MD, PhD

Follow Contact

Article

Phase 1 Study of Tru-016, An Anti-CD37 SMIP™ Protein in Naïve and Relapsed and/or Refractory CLL Patients

Blood (2011)

Farrukh T Awan, Georgia Regents University
John M. Pagel, Fred Hutchinson Cancer Research Center
Leslie A Andritsos, Ohio State University
Ajay K. Gopal, Fred Hutchinson Cancer Research Center
Richard R. Furman, Cornell University
Stephen Spurgeon, Oregon Health & Science University
Delva Deauna-Limayo, Nevada Cancer Institute
Scott Stromatt
John C. Byrd, Ohio State University

Link

Disciplines

Medicine and Health Sciences and
Immunology and Infectious Disease

Publication Date

November 18, 2011

Citation Information

Farrukh T Awan, John M. Pagel, Leslie A Andritsos, Ajay K. Gopal, et al.. "Phase 1 Study of Tru-016, An Anti-CD37 SMIP™ Protein in Naïve and Relapsed and/or Refractory CLL Patients" Blood Vol. 118 Iss. 21 (2011) p. 1792 - 1792
Available at: http://works.bepress.com/john-pagel/169/